Novartis to buy Avidity Biosciences in $12B deal to boost rare disease pipeline (NVS:NYSE)

Core Viewpoint - Novartis is set to acquire Avidity Biosciences for $12 billion in an all-cash deal, enhancing its portfolio in rare muscle disorder treatments [2] Group 1: Acquisition Details - The acquisition will be conducted in cash, totaling $12 billion [2] - Avidity Biosciences is based in California and is publicly traded on NASDAQ [2] Group 2: Strategic Implications - This acquisition aims to strengthen Novartis's offerings in the treatment of rare muscle disorders [2]